Recurrent Melanoma Completed Phase 2 Trials for DB00853 (Temozolomide)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00072163Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to MelanomaTreatment